Atlas Molecular Pharma´s business model is to exploit its innovative, cutting-edge and proprietary platform technology approach, which combined with the expertise of its high calibre and experienced team will deliver candidate drugs for patients suffering from devastating Rare and Ultra-Rare Diseases.
Our de-risked strategy will create value by delivering candidate drugs for multiple diseases suitable for pre-clinical licensing to larger Biotech and Pharma partners, positioning Atlas Molecular Pharma as a “Partner of Choice”.
Additional upside will be created by continuing to build a proprietary chemical resource/”drug discovery engine” suitable for forming potential collaborations/alliances with Biotech and Pharma partners.
Desarrollo de una formulación oral de ciclopirox para el tratamiento de la porfiria eritropoyética congénita
Referencia del proyecto: